Orris

Indication of postmenopausal hormone replacement therapy

Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Based on authoritative textbook sources, here is a comprehensive overview of the indications for postmenopausal hormone replacement therapy (HRT):

Indications for Postmenopausal Hormone Replacement Therapy (HRT)

1. Vasomotor Symptoms (Primary Indication)

The most common and well-established indication. The decline in ovarian estrogen at menopause causes hot flashes, chilly sensations, inappropriate sweating, and paresthesias in the majority of women. Estrogen therapy is the most efficacious pharmacotherapy for these symptoms and is considered specific treatment. When prescribed for this purpose, the minimum dose and duration should be used, as hot flashes typically diminish within several years. — Goodman & Gilman's Pharmacological Basis of Therapeutics

2. Urogenital Atrophy

Estrogen deficiency leads to thinning of the vaginal epithelium, vaginal dryness, and urogenital atrophy. HRT — particularly low-dose vaginally administered estrogens — effectively ameliorates these genitourinary symptoms. — Goodman & Gilman's; Berek & Novak's Gynecology

3. Prevention of Osteoporosis and Fractures

Postmenopausal estrogen deficiency markedly increases the risk of bone loss. Estrogen replacement:
  • Slows bone loss and improves bone density
  • Reduces the incidence of compression fractures of the vertebrae and minimal-trauma fractures of the hip and wrist
However, current guidelines no longer recommend HRT as a primary management tool for osteoporosis given associated risks. It is a secondary option when other therapies are unsuitable. — Medical Physiology (Boron & Boulpaep); Goodman & Gilman's; Goldman-Cecil Medicine

4. Menopausal Syndrome (General)

HRT is indicated to alleviate menopausal syndrome broadly — the constellation of symptoms resulting from estrogen deficiency including mood changes, sleep disturbances, and somatic symptoms. — Medical Physiology

5. Decreased Risk of Colorectal Cancer

Clinical trial data (Women's Health Initiative) demonstrated a 26% reduction in the incidence of colon cancer with estrogen-progestin combined HRT. — Goodman & Gilman's

Current Prescribing Principles

  • Individualized therapy: HRT is no longer recommended for broad segments of the population. The decision must be individualized based on the patient's symptom burden, baseline risk for cardiovascular disease and breast cancer, age, and time since menopause onset. — Textbook of Family Medicine 9e
  • Timing ("timing hypothesis"): Benefits are more favorable when HRT is initiated before age 60 or within 10 years of menopause onset, especially in women with low cardiovascular and breast cancer risk. — Guyton & Hall Medical Physiology
  • Lowest dose, shortest duration: Regardless of regimen, the minimum effective dose for the shortest necessary duration is recommended. — Goodman & Gilman's
  • Add progestin in women with intact uterus: Unopposed estrogen increases endometrial carcinoma risk 5–15 fold; a progestin must be co-administered unless the patient has had a hysterectomy. — Goodman & Gilman's; Medical Physiology

Key Risks (Contraindications Context)

HRT is not routinely prescribed due to documented risks, particularly with combined estrogen-progestin regimens:
  • Increased breast cancer risk (with combined CEE + MPA: ~25% relative risk increase)
  • Venous thromboembolism and deep vein thrombosis (DVT)
  • Stroke
  • Cardiovascular disease (especially when initiated >10 years post-menopause)
  • Cognitive decline
The risk-benefit calculation depends heavily on the individual patient's profile. — Guyton & Hall; Textbook of Family Medicine 9e; Goodman & Gilman's
Summary: The primary, well-supported indication for postmenopausal HRT is relief of moderate-to-severe vasomotor symptoms in carefully selected women. Secondary benefits include urogenital atrophy treatment, bone preservation, and reduced colorectal cancer risk. HRT is no longer recommended as a preventive strategy for cardiovascular disease or as first-line therapy for osteoporosis.
This is a shared conversation. Sign in to Orris to start your own chat.